Galectin Therapeutics (GALT) Insider Trading & Ownership $1.28 -0.04 (-3.03%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$1.12 -0.16 (-12.11%) As of 09:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Galectin Therapeutics (NASDAQ:GALT) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage50.10%Number OfInsiders Buying(Last 12 Months)5Amount OfInsider Buying(Last 12 Months)$48,945.70Number OfInsiders Selling(Last 12 Months)4Amount OfInsider Selling(Last 12 Months)$162,703.90 Get GALT Insider Trade Alerts Want to know when executives and insiders are buying or selling Galectin Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address GALT Insider Buying and Selling by Quarter Remove Ads Galectin Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/30/2024Harold H ShlevinDirectorBuy6,500$1.16$7,540.00 12/24/2024Richard A Jr. ZordaniDirectorBuy10,000$0.82$8,200.00 12/23/2024Jack W CallicuttCFOSell40,000$0.89$35,600.00 12/23/2024Joel LewisCEOSell56,000$0.89$49,840.00 12/23/2024Khurram JamilInsiderSell13,654$0.88$12,015.52 10/23/2024Kary EldredDirectorBuy500$2.60$1,300.00 10/16/2024Kevin D FreemanDirectorBuy5,000$2.70$13,500.00 8/23/2024Richard A Jr. ZordaniDirectorBuy1,759$2.30$4,045.70 4/30/2024Richard A Jr. ZordaniDirectorBuy1,000$3.52$3,520.00 4/24/2024Joel LewisCEOBuy1,000$3.39$3,390.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 4/22/2024James C CzirrMajor ShareholderSell21,323$3.06$65,248.38 4/22/2024Kevin D FreemanDirectorBuy2,500$2.98$7,450.00 (Data available from 1/1/2013 forward) GALT Insider Trading Activity - Frequently Asked Questions Who is on Galectin Therapeutics's Insider Roster? The list of insiders at Galectin Therapeutics includes Harold H Shlevin, Jack W Callicutt, James C Czirr, Joel Lewis, Kary Eldred, Kevin D Freeman, Khurram Jamil, and Richard A Jr. Zordani. Learn more on insiders at GALT. What percentage of Galectin Therapeutics stock is owned by insiders? 50.10% of Galectin Therapeutics stock is owned by insiders. Learn more on GALT's insider holdings. Which Galectin Therapeutics insiders have been buying company stock? The following insiders have purchased GALT shares in the last 24 months: Harold H Shlevin ($7,540.00), Joel Lewis ($3,390.00), Kary Eldred ($5,055.42), Kevin D Freeman ($20,950.00), and Richard A Jr. Zordani ($15,765.70). How much insider buying is happening at Galectin Therapeutics? Insiders have purchased a total of 30,357 GALT shares in the last 24 months for a total of $52,701.12 bought. Which Galectin Therapeutics insiders have been selling company stock? The following insiders have sold GALT shares in the last 24 months: Jack W Callicutt ($35,600.00), James C Czirr ($65,248.38), Joel Lewis ($49,840.00), and Khurram Jamil ($12,015.52). How much insider selling is happening at Galectin Therapeutics? Insiders have sold a total of 130,977 Galectin Therapeutics shares in the last 24 months for a total of $162,703.90 sold. Galectin Therapeutics Key ExecutivesMr. Joel Lewis (Age 54)President, CEO & Director Compensation: $907.72k1 recent tradesMr. Jack W. Callicutt CPA (Age 57)CFO, Treasurer & Corporate Secretary Compensation: $521.47k1 recent tradesDr. Pol F. Boudes M.D. (Age 67)Ph.D., Chief Medical Officer Compensation: $730.33kRobert TrittGeneral CounselMr. Jeff KatstraHead of CMC & Pharmaceutical DevelopmentMs. Beth KnowlesExecutive Assistant & Officer Manager More Insider Trading Tools from MarketBeat Related Companies Upstream Bio Insider Transactions Cartesian Therapeutics Insider Transactions Entrada Therapeutics Insider Transactions Eton Pharmaceuticals Insider Transactions Mereo BioPharma Group Insider Transactions Revance Therapeutics Insider Transactions Rapport Therapeutics Insider Transactions Solid Biosciences Insider Transactions Heron Therapeutics Insider Transactions Allogene Therapeutics Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Casey’s General Stores Insider Buys Shares of This Must-Own StockNVIDIA Insiders Sell: This Is What It Means for the Market Top 3 Insider Stock Buys in March—Are They Still Good in April?Grocery Outlet Insider and Institutional Buyers Signal BottomSentinelOne Insider Selling? Why Investors Should Stay Bullish This page (NASDAQ:GALT) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GALT Stock Free GALT Stock Alerts